High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label‐Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis: 2038. (October 2015) - Reau, Nancy; Muir, Andrew J.; Pockros, Paul; Reddy, Rajender K.; Pedrosa, Marcos; Larsen, Lois; Enejosa, Jeffrey; Howell, Charles